Colon Cancer is an indication for drug development with over 480 pipeline drugs currently active. According to GlobalData, preregistered drugs for Colon Cancer have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Colon Cancer compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Colon Cancer

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Colon Cancer overview

Colon cancer, is a type of cancer that begins in the colon, which is the part of the large intestine. It typically develops from precancerous growths called polyps, which can become cancerous over time. Colon cancer often develops slowly over several years, and it usually begins as small, noncancerous (benign) clumps of cells known as adenomatous polyps. Over time, some of these polyps may become cancerous. Symptoms include Changes in bowel habits, such as more frequent diarrhea or constipation, Rectal bleeding or blood in the stool, Ongoing discomfort in the belly area, such as cramps, gas or pain.

For a complete picture of PTSR and LoA scores for drugs in Colon Cancer, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.